成都苑东生物制药股份有限公司 独立董事关于第三届董事会第十二次会议 相关事项的独立意见 我们作为成都苑东生物制药股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券交易所科创板 股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《公司章程》 及公司《独立董事工作制度》等有关规定，本着对公司、全体股东及投资者负责 的态度，基于独立判断的立场，对公司第三届董事会第十二次会议审议的《关于 <公司 2023 年半年度募集资金存放与使用情况的专项报告>的议案》发表独立意 见如下： 报告期内，公司募集资金存放与使用情况符合《上海证券交易所科创板股票 上市规则》、《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号—— 规范运作》等法律法规和公司《募集资金管理制度》等制度文件的规定；公司对 募集资金进行了专户存储和专项使用，使用部分闲置募集资金进行现金管理事项 已履行了必要且合规的决策程序，并及时履行了相关信息披露义务，不存在变相 改变募集资金用途和损害股东利益的情况，不存在违规使用募集资金的情形。因 此，我们一致同意该议案。 独立董事：JIN L ...

截至 2023 年 6 月 30 日止，结余募集资金（含利息收入扣除银行手续费的 净额）余额为 10,318.27 万元。具体情况如下： 单位：人民币万元 成都苑东生物制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 成都苑东生物制药股份有限公司（以下简称"苑东生物"、"本公司"或"公 司"）董事会根据《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规范运作》及相关格式指引的要求，编制了截至 2023 年 6 月 30 日的《2023 年半年度募集资金存放与使用情况的专项报告》。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 公司经中国证券监督管理委员会"证监许可[2020]1584 号"《关于同意成都 苑东生物制药股份有限公司首次公开发行股票注册的批复》同意注册，向社会 公开发行了人民币普通股（A 股）股票 3,009.00 万股，发行价为每股人民币为 44.36 元，共计募集资金总额为人民币 1,334,792,400.00 元，扣除发行费用（不 含税）人民币 112,083,983.49 元，本次募集资金净额为 1,222,708,416.511元。上 ...

证券代码：688513 证券简称：苑东生物 公告编号：2023-031 成都苑东生物制药股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一）回购股份的目的和用途 风险提示： 1 拟回购股份的用途：公司拟在未来适宜时机使用本次回购的股份实施员工 持股计划或股权激励，并在股份回购实施结果暨股份变动公告披露后三年 内完成股份转让；若公司未能在规定期限内转让完毕，则将依法履行减少 注册资本的程序，未转让的股份将被注销。 拟回购价格：不超过人民币 73 元/股（含），该价格不高于公司董事会通过 回购决议前 30 个交易日公司股票交易均价的 150%。 拟用于回购股份的资金总额：不低于人民币 10,000 万元（含）且不超过人 民币 20,000 万元（含）。 回购期限：自董事会审议通过回购股份方案之日起 12 个月内。 回购资金来源：公司自有资金。 相关股东是否存在减持计划：截至本公告披露之日，公司控股股东、实际 控制人及其一致行动人、公司董事、监事及高级管理 ...

证券代码：688513 证券简称：苑东生物 公告编号：2023-030 成都苑东生物制药股份有限公司 第三届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第三届董事会第十一次会 议于 2023 年 8 月 14 日以现场和通讯相结合的方式召开。会议通知已于 2023 年 8 月 11 日送达全体董事。本次会议由董事长王颖主持，应出席董事 9 名，实际 出席董事 9 名。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 等相关法规和《成都苑东生物制药股份有限公司章程》规定，会议形成的决议合 法有效。 二、董事会会议审议情况 经与会董事审议，形成决议如下： （一）审议通过《关于以集中竞价交易方式回购股份方案的议案》 经审议，董事会认为：公司本次回购股份是基于对公司未来发展的信心和对 公司长期投资价值的认可，有利于充分调动公司员工的积极性，提高凝聚力，有 效地将股东利益、公司利益和员工个人利益紧密结合在一起，促进公司稳定 ...

成都苑东生物制药股份有限公司 独立董事关于第三届董事会第十一次会议 相关事项的独立意见 我们作为成都苑东生物制药股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券交易所科创板 股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《公司章程》 及公司《独立董事工作制度》等有关规定，本着对公司、全体股东及投资者负责 的态度，基于独立判断的立场，对公司第三届董事会第十一次会议审议的《关于 以集中竞价交易方式回购股份方案的议案》发表独立意见如下： 1、公司本次回购股份符合《公司法》、《证券法》以及《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等法律法规、规范性文件以及《公司 章程》等有关规定，回购股份的审议和决策程序合法合规。 2、公司本次回购股份的用途为员工持股计划或股权激励，有利于充分调动 公司员工的积极性，提高团队凝聚力和竞争力，有效地将股东利益、公司利益和 员工利益紧密结合，促进公司稳定、健康、可持续发展，因此，本次股份回购具 有必要性。 3、本次回购资金来源为公司自有资金，不会对公司的经营、财务和未来发 展产生重大影响，公司 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥277,853,183.77, representing a year-on-year increase of 3.31%[5] - The net profit attributable to shareholders for the same period was ¥60,985,871.41, reflecting a growth of 13.35% compared to the previous year[5] - The basic earnings per share for Q1 2023 stood at ¥0.51, which is an increase of 13.33% year-on-year[6] - The net profit for Q1 2023 was CNY 60,985,871.41, representing an increase of 13.8% compared to CNY 53,801,911.59 in Q1 2022[19] - The operating profit for Q1 2023 was CNY 68,278,212.94, up from CNY 57,338,282.15 in the same period last year, indicating a growth of 19.4%[22] - The total operating expenses decreased to CNY 244,172,808.16 from CNY 282,959,361.73 in Q1 2022, a reduction of 13.7%[22] Research and Development - Research and development expenses totaled ¥51,336,628.31, accounting for 18.48% of operating revenue, a decrease of 1.34 percentage points from the previous year[6] - Research and development expenses increased to CNY 50,088,561.76, compared to CNY 45,192,135.02 in Q1 2022, reflecting an increase of 6.4%[22] Cash Flow and Assets - The net cash flow from operating activities was ¥32,933,694.58, showing a decline of 11.54% compared to the same period last year[5] - The cash flow from operating activities was CNY 32,933,694.58, a decrease from CNY 37,228,404.83 in the previous year, down by 11.5%[22] - The cash flow from investment activities showed a net outflow of CNY 289,811,019.34, improving from a net outflow of CNY 512,688,220.48 in Q1 2022[23] - Cash and cash equivalents decreased to RMB 620,514,361.50 from RMB 830,966,815.87 at the end of 2022, a decline of about 25.3%[13] - The company reported a cash and cash equivalents balance of CNY 614,284,188.64 at the end of Q1 2023, compared to CNY 590,296,812.64 at the end of Q1 2022, an increase of 4.0%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,643[9] - The largest shareholder, Wang Ying, holds 41,900,000 shares, representing 34.89% of the total shares[9] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,098,765,523.95, an increase of 2.69% from the end of the previous year[6] - Current assets as of March 31, 2023, totaled RMB 1,742,813,162.60, compared to RMB 1,709,122,350.80 at the end of 2022, reflecting an increase of approximately 1.96%[13] - Total liabilities as of March 31, 2023, were RMB 592,973,210.53, up from RMB 573,080,516.96 at the end of 2022, representing an increase of about 3.2%[15] - Non-current assets totaled RMB 1,355,952,361.35, an increase from RMB 1,308,417,882.31 at the end of 2022, reflecting a growth of about 3.63%[14] - The company's retained earnings increased to RMB 881,245,083.61 from RMB 820,259,212.19 at the end of 2022, showing an increase of approximately 7.4%[15] Operating Costs - Total operating costs for Q1 2023 were RMB 226,451,481.30, slightly up from RMB 225,745,308.15 in Q1 2022, indicating a marginal increase of about 0.31%[17] - The company reported a net profit margin improvement, with total operating income growth outpacing total operating costs growth in Q1 2023[17] - The total revenue from operating activities was CNY 255,609,521.27, down from CNY 299,663,469.03 in Q1 2022, a decrease of 14.7%[22] Other Income - The company achieved other income of CNY 10,914,075.81, compared to CNY 6,027,818.28 in Q1 2022, marking an increase of 81.5%[22] - The company reported non-recurring gains of ¥14,655,333.08 for the period, after accounting for tax effects[7]

Financial Performance - The company's operating revenue for 2022 was approximately CNY 1.17 billion, representing a 14.43% increase from CNY 1.02 billion in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately CNY 246.52 million, a 6.06% increase from CNY 232.43 million in 2021[23]. - The net profit after deducting non-recurring gains and losses was approximately CNY 164.70 million, reflecting a 20.16% increase from CNY 137.07 million in 2021[23]. - The company's total assets at the end of 2022 were approximately CNY 3.02 billion, an 8.73% increase from CNY 2.78 billion at the end of 2021[23]. - The basic earnings per share for 2022 was CNY 2.05, a 5.67% increase from CNY 1.94 in 2021[24]. - The company's net assets attributable to shareholders at the end of 2022 were approximately CNY 2.44 billion, a 6.67% increase from CNY 2.29 billion at the end of 2021[23]. - The total revenue for the reporting period reached ¥60,841.99 million, with a net profit of ¥12,454.41 million, reflecting a significant increase in performance[89]. - The company achieved total revenue of CNY 1,170,512,900.63, representing a year-on-year growth of 14.43%[113]. - The net profit attributable to shareholders was CNY 246,520,800, reflecting a year-on-year increase of 6.06%[113]. Research and Development - Research and development expenses accounted for 22.65% of operating revenue in 2022, up from 20.41% in 2021[24]. - The total R&D investment for the year reached ¥265.14 million, an increase of 27.02% compared to the previous year[74]. - The proportion of R&D investment to operating income rose to 22.65%, up by 2.24 percentage points from the previous year[74]. - The company has over 10 Class 1 innovative drugs in research, with 3 currently undergoing clinical trials, including the oral long-acting hypoglycemic drug, Yograstatin tablets[50][51]. - The company is focusing on innovative drug formulation techniques, achieving a stable production process for EP-0112T, a nasal spray with significant technical challenges[91]. - The company has reported a total R&D investment of 81,481.69 million RMB, representing 29.38% of its operating revenue, which is significantly higher than the industry average[173]. - The company's R&D investment as a percentage of net assets was 10.85%, indicating a strong commitment to innovation and development[173]. - The company capitalized 12.96% of its R&D expenditures, reflecting a strategic approach to managing its research investments[173]. Market Position and Strategy - The company has a strong market position, with three of its main products ranking first in market share, including sodium namifen injection, ibuprofen injection, and ibandronic acid sodium injection[62]. - The company is focusing on building a differentiated competitive advantage in innovative drug products, particularly in the fields of anesthesia and oncology[36][37]. - The company is actively expanding its international presence, particularly in the opioid detoxification and emergency medication product lines[55]. - The company is focusing on integrating raw materials and formulations to ensure supply chain security amid global uncertainties and increasing competition in the biopharmaceutical sector[65]. - The company is strategically expanding its CMO/CDMO business to enhance profitability and strengthen its integrated supply chain capabilities[98]. - The company aims to maintain competitiveness under centralized procurement policies by enhancing operational efficiency and continuously launching new products[146]. - The company is focusing on expanding its product portfolio with new drug approvals and ongoing clinical trials for various therapeutic areas[160]. Risks and Compliance - The company has detailed various risks and countermeasures in its annual report, urging investors to pay attention to investment risks[4]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors[7]. - The company faces risks from national volume-based procurement and medical insurance payment adjustments, which may lead to price reductions for some products[105]. - The company has implemented a complete quality management system from drug development to commercial production, ensuring strict quality control[99]. Corporate Governance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures for providing guarantees[9]. - The company has not reported any instances of more than half of the board members being unable to guarantee the authenticity of the annual report[9]. - The company has not disclosed any special arrangements for corporate governance[9]. Internationalization and Innovation - The internationalization strategy has seen the completion of 2 ANDA submissions, with the hydrochloride injection of Nalfurafine and Nicardipine receiving priority review and acceptance from the FDA[39][40]. - The company has successfully passed the Korean MFDS certification and FDA inspections for raw materials, marking significant progress in internationalization[43]. - The company is committed to internationalization, with plans to complete five international registration projects and enhance its product pipeline for the U.S. market[198]. - The company is focusing on innovation and the development of next-generation biotechnologies to enhance its product offerings[191]. Financial Management - Government subsidies accounted for CNY 65,927,300, which is 25.16% of the total profit, indicating potential risk if policies change[112]. - Operating costs increased by 36.77% year-on-year, primarily due to higher product sales volumes[115]. - The company's investment activities generated a net cash outflow of CNY 405,702,351.20, primarily due to increased construction investments[115]. - The net cash flow from financing activities improved to ¥39,696,297.46 from -¥56,396,555.50, mainly due to increased short-term borrowings and discounted notes receivable[136]. Talent Development - The company has established a comprehensive talent development strategy, including the establishment of a Shanghai Research Institute to attract top talent and enhance innovation capabilities[46]. - The company has a research and development team of over 400 people and has established a national-level enterprise technology center and postdoctoral research workstation[95]. - The R&D personnel count increased to 407, representing 30.76% of the total workforce, with an average salary of ¥23.11 million per person[94].

证券代码：688513 证券简称：苑东生物 公告编号：2023-017 成都苑东生物制药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 会议召开方式：上证路演中心网络互动 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日 发布公司 2022 年年度报告及 2022 年度利润分配预案，为加强与投资者的深入交 流，使投资者更加全面、深入地了解公司经营成果、财务指标等情况，公司计划 于 2023 年 04 月 21 日（星期五）上午 11:00 - 12:00 举行 2022 年度业绩暨现金分 红说明会，就投资者关心的问题进行交流，欢迎广大投资者积极参与。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果、 财务指标及 2022 年度现金分红的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （ ...

Financial Performance - The company's revenue for Q3 2022 was ¥322,179,501.72, representing a year-over-year increase of 17.27%[6] - Net profit attributable to shareholders for Q3 2022 was ¥60,856,356.20, showing a decrease of 11.46% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥38,517,219.50, an increase of 21.54% year-over-year[6] - Total operating revenue for the first three quarters of 2022 reached ¥897,590,018.32, an increase of 16.1% compared to ¥773,436,181.18 in the same period of 2021[24] - Net profit for the first three quarters of 2022 was ¥195,492,474.81, representing a growth of 5.5% from ¥186,075,903.15 in 2021[31] - Basic earnings per share for Q3 2022 were ¥0.51, down 10.53% compared to the same period last year[10] - Basic earnings per share for the first three quarters of 2022 were ¥1.63, compared to ¥1.55 in the same period of 2021[33] Research and Development - R&D investment totaled ¥75,772,263.90 in Q3 2022, up 41.55% from the previous year, accounting for 23.52% of revenue[10] - Research and development expenses for the first three quarters of 2022 amounted to ¥165,078,988.64, up 11.6% from ¥147,822,178.55 in the previous year[27] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥3,003,472,092.39, an increase of 8.22% from the end of the previous year[10] - The company's total current liabilities increased to ¥563,972,583.20 from ¥432,458,963.97, which is an increase of approximately 30.4%[22] - The total liabilities as of the end of the reporting period were ¥609,933,988.70, an increase from ¥483,601,755.82 in the previous year[24] - The total equity attributable to shareholders reached ¥2,393,538,103.69, up from ¥2,291,664,728.59 in 2021[24] Cash Flow - The company reported a net cash flow from operating activities of ¥141,346,062.05 for the year-to-date period, a decrease of 2.09% year-over-year[10] - Cash inflow from operating activities totaled ¥981,016,081.53 in the first three quarters of 2022, an increase from ¥909,989,358.80 in 2021[36] - The net cash flow from operating activities was $141,346,062.05, a decrease from $144,363,177.82 in the previous period[37] - Cash outflow from investing activities totaled $2,310,797,186.24, down from $3,297,696,338.54 year-over-year[37] - The net cash flow from investing activities was -$673,657,053.10, an improvement from -$943,287,000.18 in the prior period[37] - Cash inflow from financing activities amounted to $147,373,150.35, compared to $10,000,000.00 previously[37] - The net cash flow from financing activities was $52,188,019.78, a recovery from -$76,362,236.06 in the last period[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,138[13] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 2.57%, a decrease of 0.54 percentage points year-over-year[10] - Government subsidies recognized in Q3 2022 amounted to ¥17,921,133.78, contributing to non-recurring gains[10] - The company's cash and cash equivalents decreased to ¥559,858,478.86 from ¥1,050,695,494.02 year-over-year, representing a decline of approximately 46.8%[19] - The trading financial assets increased significantly to ¥766,076,763.67 from ¥453,840,935.17, marking an increase of approximately 68.8%[19] - Accounts receivable rose to ¥137,554,068.67 from ¥112,427,878.56, reflecting an increase of about 22.3%[19] - The company's inventory increased to ¥123,781,058.87 from ¥103,682,790.76, representing an increase of about 19.4%[19] - The company's long-term equity investments were recorded at ¥98,030,208.71, with no previous year data available for comparison[22] - The company reported a significant increase in other non-current financial assets, totaling ¥22,000,000.00, with no previous year data available[22] Business Developments - The company has not reported any significant new product developments or market expansions during the reporting period[16] - There were no significant mergers or acquisitions disclosed in the third quarter report[16]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 25%[19] - The net profit attributable to shareholders was RMB 100 million, with a growth rate of 15% compared to the same period last year[19] - The company's operating revenue for the first half of 2022 was RMB 575,410,516.60, representing a 15.38% increase compared to RMB 498,701,178.06 in the same period last year[26] - The net profit attributable to shareholders for the same period was RMB 134,636,118.61, up 14.74% from RMB 117,343,408.61 year-on-year[26] - The net profit after deducting non-recurring gains and losses increased by 25.44%, reaching RMB 105,094,083.93 compared to RMB 83,782,428.46 in the previous year[26] - The company's cash flow from operating activities saw a significant increase of 52.84%, totaling RMB 96,862,879.24, compared to RMB 63,375,926.37 in the same period last year[26] - The company maintains a strong cash position with RMB 200 million in cash reserves, ensuring liquidity for ongoing operations and investments[19] - The company reported a total revenue of 21,564.6 million, with a year-on-year increase of 62,100.39 million and a net profit of 4,942.69 million, representing a growth of 7%[90] - The company achieved operating revenue of 575.41 million yuan, an increase of 15.38% year-on-year[106] - The net profit attributable to the parent company was 134.64 million yuan, up 14.74% year-on-year, driven by increased sales of key products[106] Research and Development - The company is investing RMB 50 million in R&D for innovative drug development, focusing on competitive generic therapies[19] - The company's R&D investment accounted for 20.32% of operating revenue, an increase of 1.41 percentage points compared to 18.91% in the previous year[30] - The company's R&D expenditure reached 117 million CNY, accounting for 20.32% of annual revenue[63] - The total R&D investment amounted to ¥116,898,207.13, representing a 23.98% increase compared to ¥94,290,505.20 in the same period last year[73] - The R&D team expanded to 370 personnel, with a slight decrease in the proportion of R&D staff to total employees at 29.41%[5] - The company has over 50 ongoing projects, with 20% being innovative drug projects, including one Class 1 new drug in Phase III clinical trials[101] - The company has established a complete quality management system for drug development and commercial production, with multiple products certified by the FDA and EMA[103] - The company is focusing on expanding its capabilities in biopharmaceuticals, with ongoing development of monoclonal antibodies and dual-specific antibodies[110] - The company has submitted a total of 7 registration applications for formulations and APIs, and received 2 new domestic invention patents, enhancing its product pipeline and market competitiveness[111] Market Expansion and Product Development - User data indicated an increase in active users by 30%, reaching a total of 1.5 million users by the end of June 2022[19] - The company plans to launch two new products in Q4 2022, aiming to capture a larger market share in the biopharmaceutical sector[19] - Future outlook includes a projected revenue growth of 20% for the second half of 2022, driven by new product launches and market expansion strategies[19] - Market expansion efforts include entering two new international markets by the end of 2022, targeting a 10% increase in overseas sales[19] - The company is focused on expanding its product portfolio in the fields of anesthesia, diabetes, cardiovascular, and oncology, aiming to meet unmet clinical needs domestically and internationally[34] - The company is actively pursuing clinical trials and research to advance its product pipeline, with several projects at various stages of development[81] - The company is focusing on expanding its product portfolio in the cardiovascular and analgesic markets, with several products already submitted for registration[83][85] Innovation and Technology - The company has successfully commercialized 32 high-end chemical drugs, including 5 domestic first generic products and 22 products that have passed consistency evaluation[35] - The company has developed six core technologies, including drug crystal form integration innovation and controlled-release technology[58] - The company has established a micro-reaction continuous flow technology platform, successfully achieving breakthroughs in key material synthesis[62] - The company has achieved significant technological advancements in the production of various injectable drugs, including overcoming challenges related to stability and purity[83] - The company is enhancing its sales model by improving its distribution network and academic promotion strategies to adapt to national drug procurement policies[49] Risk Management and Compliance - Risk factors identified include regulatory changes and market competition, with mitigation strategies outlined in the report[19] - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[19] - The company emphasizes adherence to legal and regulatory requirements regarding share transfers, maintaining compliance with stock exchange rules[197] - The company commits to not reducing its shareholdings during specific periods related to major violations or delisting risks, ensuring shareholder confidence[197] Environmental Responsibility - The company was recognized as a national green factory in December 2021, indicating a commitment to environmental protection[166] - The wastewater treatment facility has a processing capacity of 300 cubic meters per day, while the actual discharge is 201 cubic meters per day[166] - The company has implemented measures to ensure that major pollutants are effectively treated during production processes[166] - The company has upgraded its wastewater treatment system to a capacity of 400 cubic meters per day, ensuring compliance with discharge standards[172] - The company has received pollution discharge permits valid until 2026 for its operations[177] - The company has maintained compliance with environmental regulations, with no instances of exceeding pollutant discharge limits reported during the reporting period[185]